HOME >> MEDICINE >> NEWS
The Lancet Oncology (TLO)

Billions of dollars are currently being spent on the search for effective drugs that will stop disease before it happens. Advances in genetic testing are providing more opportunities to find out which diseases people are likely to be at risk of developing--but this knowledge has put huge pressure on the medical profession to come up with ways of avoiding disease altogether. This month's leading edge questions the ethical issues involved in chemoprevention and highlights the difficulties in obtaining reliable data from chemoprevention clinical trials. It concludes: "Genetic tests have created a demand for chemoprevention that is threatening to push medicine to its limits; health services could be stretched beyond capacity because they are treating healthy people as well as the sick. To stop this snowball effect it is essential that one simple idea is kept in mind: you can spend all the money in the world on preventive medicine, but when people won't even stop smoking, can it really work?"

STOMACH CANCER - THE LATEST TARGET FOR THE 'MAGIC BULLET'

Gastrointestinal stromal tumours (GISTs) are the most recent cancer type to be targeted by the most effective new drug of recent years--imatinib mesylate. Effective treatment of GISTs has been hindered in the past by their characteristic resistance to conventional chemotherapy and persistent misclassification of these tumours in clinical studies has made pre-2000 data difficult to interpret. However, it is now known that most GISTs contain a mutation in the KIT tyrosine kinase, which means they are an ideal target for imatinib. In their review, Heikki Joensuu and colleagues discuss the recent advances in understanding of these difficult-to-treat tumours and discusses the impact of imatinib on outcome for patients with GISTs. The authors conclude that imatinib "has provided physicians with a well-tolerated and highly effective therapeutic option for a disease for which no systemic therapy existed previously".
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
30-Oct-2002


Page: 1 2

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Infectious Diseases (TLID)
5. The Lancet Neurology November press release
6. Lancet readers to join WHO election debate
7. The Lancet Oncology press release
8. The Lancet Neurology October press release
9. The Lancet neurology press release
10. The Lancet Neurology press release
11. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2020)... SEATTLE (PRWEB) , ... September 01, 2020 , ... ... that it has completed $3 million convertible note financing, which will be used ... , With the funds from this financing, the company will continue to expand ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... Health Network (AHN), are joining biomedical engineers from Carnegie Mellon University (CMU) to ... for cardiac patients who have undergone open heart surgery. , The AGH/CMU team ...
(Date:8/31/2020)... ... August 31, 2020 , ... Want to get moving, break up your ... Foundation (CPARF) is thrilled to launch its fourth annual STEPtember campaign in the United ... STEPtember meets everyone wherever they are at this moment — encouraging people to move ...
(Date:8/31/2020)... ... August 31, 2020 , ... The pandemic and topsy-turvy economic outlook continues to put financial ... look for ways to trim the fat from our monthly expenses and put more into ... also important that you have a financial safety net in place in case something were ...
(Date:8/31/2020)... ... August 31, 2020 , ... Bonde ... for patients with advanced heart failure, today announced that the company has been ... of $555,358 from the National Heart, Lung, and Blood Institute of the National ...
Breaking Medicine News(10 mins):
(Date:8/31/2020)... SEATTLE (PRWEB) , ... August 31, 2020 , ... ... technology research and advisory guide, has named Cloudticity a Gold winner in the ... are industry and peer recogniti o ns from Network Products Guide ...
(Date:8/28/2020)... ... ... Dr. Mark Surrey has been in practice for over 25 years. ... in the Department of OBGYN at UCLA’s David Geffen School of Medicine. , ... and is a Clinical Director of Fellowship Training for UCLA & Cedars Sinai Reproductive ...
(Date:8/27/2020)... ... 27, 2020 , ... InfoMC, a leading provider of cloud-based ... 2020 System and Organizational Controls (SOC) 1® Type 2 and SOC 2® Type ... These achievements reflect their long-standing commitment to privacy, security, and risk management, while ...
Breaking Medicine Technology:
Cached News: